<Anchor>
To end this discomfort and go back to the pre-corona, we need a vaccine, but we will give you some news of the vaccine.
It was confirmed that the UK's AstraZeneca vaccine, which had an intermediate clinical trial result yesterday (23rd), was already produced by our company in Korea.
In addition, the development of domestic vaccines is also speeding up.
Reporter Kim Hyung-rae on the report.
<Reporter> There are
currently three vaccine candidates being developed in Korea.
Two types of DNA vaccines containing specific genes to make antibodies and a synthetic antigen vaccine that recombined some proteins of the virus.
One DNA vaccine was approved for clinical trials in June and a synthetic antigen vaccine yesterday.
The remaining DNA vaccine is also awaiting approval of the clinical trial plan by the Ministry of Food and Drug Safety.
[Kwon Jun-wook/President of the National Institute of Health: It is judged that all three kinds of domestic vaccine candidates may be able to initiate clinical trials as soon as possible within the year.] If the
clinical trial is successful, synthetic antigen vaccines will be conducted in the second half of next year, and DNA vaccines will be in the next year. It is expected that vaccination will be possible.
Among overseas vaccines, SK Bioscience, a Korean company, has begun to consign AstraZeneca vaccine to the UK.
The industry predicted that "Vaccines produced in Korea are not only for clinical use, but also for sale."
The government is negotiating with the headquarters to purchase 10 million AstraZeneca vaccines, which have announced interim results of phase 3 clinical trials.
In addition to the vaccine, the health authorities explained that the development of a domestic-made COVID-19 treatment is also in progress, and that patients are currently being registered and clinical trials at 10 medical institutions.
(Video coverage: Min-cheol Kim, video editing: Sun-tak Kim)
▶ Why was Astra vaccine more effective at low doses?